Former L'Oréal President Jim Morrison, Chief Executive Officer of Emergent Health Reports Quarter over Quarter Revenue Increase of Over 2300%
New York, NY,
|
May 16, 2023 09:00 AM Eastern Daylight Time
Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space announced revenues of $340,531 for the quarter ended March 31, 2023, as compared to $14,267 for the quarter ended March 31, 2022, an increase of over 2300%. The financial statement can be viewed in its entirety at https://www.otcmarkets.com/stock/EMGE/disclosure.
Jim Morrison, former L'Oréal President and Emergent’s full time CEO stated "Q1 was a good starting point for the 'new look' EMGE. You will see the effect of many of our new business initiatives as we move into the second quarter and throughout the year. We are on track for 2023 to be a very good year."
Emergent believes it will continue increasing its revenues quarter over quarter as it expands its business internally and externally through acquisition.
Recent Developments:
On May 11, 2023, announced that its subsidiary Evolutionary Biologics, Inc. (EvoBio), a developer, manufacturer and distributor of private label regenerative medicine products and branded state-of-the-art biologic products, created in a pharmaceutical grade laboratory and manufacturing facility has executed a Product Manufacturing Agreement with a distributor of medical devices that desires to market a MSC Exosome product from EvoBio as a private label on an exclusive basis. The Company believes the new relationship will generate at least $2 million in new revenue. The press release can be viewed in its entirety here.
On May 9, 2023, announced that it has engaged BF Borgers CPA PC, a full-service audit, tax, accounting, and advisory firm, as its Public Company Accounting Oversight Board (PCAOB) qualified auditor to audit the Company’s financial statement for the two-year period ending December 31st, 2022 according to Generally Accepted Accounting Principles (GAAP). GAAP is the accounting standard adopted by the Securities and Exchange Commission (SEC) and is the default accounting standard used by companies based in the United States. The press release can be viewed in its entirety here.
On May 4, 2023, announced the execution of an Engagement Letter with Boustead Securities LLC. to act as exclusive financial advisor with respect to a planned corporate financing transaction including the private placement of securities (pre-IPO Financing) and a planned $10 million initial public offering of Emergent subsidiary PharmaZu common stock (IPO) that will apply for listing on NASDAQ with NO DILUTION to the Emergent Shareholders. PharmaZu is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including pet pharmacy, vet telehealth and pet wellness businesses. Upon the effectiveness of the IPO and listing on NASDAQ, PharmaZu plans to acquire a 49-state authorized compounding pharmacy located in West Palm Beach, FL, doing approximately $10M a year in revenue, which will serve as the backbone and fulfilment center for PharmaZu, creating a national platform throughout the United States. The raise of capital will be used for expanding PharmaZu’s business, product offerings, as well as for acquisitions. Subsequently, Emergent plans to distribute the shares of PharmaZu as a dividend to its shareholders, pro rata at NO COST to the Emergent Shareholders. The press release can be viewed in its entirety here.
The global biologics market size was valued at US $366.43 billion in 2021 and it is expected to hit over US$ 719.84 billion by 2030 with a noteworthy CAGR of 7.8% from 2022 to 2030. A biologic medication is a product that is made from live organisms and contains living organism components. Recombinant protein, tissues, allergens, genes, cells, blood components, blood, and vaccinations are all examples of biologics. Anemia, hemophilia, chronic migraine, hepatitis B, rheumatoid arthritis, inflammatory bowel disease, and other disorders and infections are treated with biologics. Various government efforts, higher share of biologics in the market, and rising use of biopharmaceuticals over chemically produced molecules, and many other factors are driving the biologics market expansion in the forecast period.
ABOUT EMERGENT HEALTH CORPORATION
Emergent curates, develops and sells products in the Regenerative Health Space. Its products comprise of ingestibles as well as topicals for the whole family. The company distributes its products online and through Content Based Shopping using Influencers to position products in their produced content throughout the United States and Internationally. Its subsidiaries; PharmaZu, is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including the pet pharmacy, vet telehealth and pet wellness businesses; Regen BioWellness, is a distributor of various products in the plant-based and regenerative medical fields. Evolutionary Biologics, is a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease. For more information, please visit Emergent's Website and Social Media on Twitter.
Before using any products, you should always consult with your Veterinarian and/or Family Doctor.
SAFE HARBOR STATEMENT
This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
FOR MORE INFORMATION, PLEASE CONTACT:
Jim Morrison, CEO
Emergent Health Corporation Website
info@emergenthealthcompany.com
Contact Details
Emergent Health Corp.
info@emergenthealthcompany.com
Company Website
